HC Wainwright Forecasts Compugen’s Q1 Earnings (NASDAQ:CGEN)

Compugen Ltd. (NASDAQ:CGEN) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Compugen in a research note issued to investors on Tuesday, March 3rd. HC Wainwright analyst S. Ramakanth expects that the biotechnology company will post earnings of ($0.09) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Compugen’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Compugen’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.36) EPS.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.55. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The business had revenue of $67.33 million during the quarter, compared to analyst estimates of $14.30 million.

Other equities analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a research note on Wednesday, January 21st. Wall Street Zen upgraded Compugen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.00.

Compugen Stock Up 7.0%

Shares of NASDAQ CGEN opened at $2.14 on Thursday. Compugen has a fifty-two week low of $1.13 and a fifty-two week high of $2.38. The firm’s 50-day simple moving average is $1.82 and its 200 day simple moving average is $1.66.

Institutional Trading of Compugen

A number of institutional investors have recently modified their holdings of CGEN. Bank Hapoalim BM bought a new stake in shares of Compugen during the 4th quarter valued at $37,000. XTX Topco Ltd bought a new position in shares of Compugen in the fourth quarter valued at approximately $104,000. Security National Bank of Sioux City Iowa IA purchased a new position in Compugen during the fourth quarter valued at approximately $38,000. Marshall Wace LLP lifted its stake in Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 61,202 shares in the last quarter. Finally, State Street Corp boosted its holdings in Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after purchasing an additional 14,701 shares during the period. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.